Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Mar 6, 2018 • 4:01 PM EST
Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences
Mar 5, 2018 • 4:01 PM EST
Ligand to Participate in Two Upcoming Investor Conferences
Feb 21, 2018 • 4:01 PM EST
Ligand Reports Fourth Quarter and Full Year 2017 Financial Results
Mar 13, 2018 • 8:30am EDT
See all events
Mar 12, 2018 • 4:30pm EDT
Dana Point, California
Feb 21, 2018 • 4:30pm EDT
Arcus Biosciences announces abstracts accepted for presentation at AACR 2018, including characterization of GLS-010… https://t.co/PkvVHqDDxD
$MLNT partner Menarini Group submits Marketing Authorization Application for delafloxacin in Europe https://t.co/YJrKXx9ine
$EXEL announces collaborator Daiichi Sankyo’s submission of regulatory filing for esaxerenone (CS-3150) in Japan https://t.co/k1RXUeS3XU